In clinics, pharmacological blockade of TNFα activity – i.e., by the neutralizing antibody infliximab or the soluble TNFαR Etanercept – used to reduce symptoms of rheumatoid arthritis or Crohn’s disease, has been since few years ago extended also to IMs, although some caution has been recommended [18], [57]–[59]. Here, TNF is linked to rheumatoid arthritis.